Fighting Cancer with Novel Antibiotics

Yatra Patel and Luke Ustick. University of Cincinnati Science and Health Department, Clermont College 4200 Clermont College Dr, Batavia, OH 45103

pately4@mail.uc.edu

Abstract. Despite current therapies, tumor relapse and therapy resistance present as significant obstacles to successful management of cancer. Cancer stem cells (CSCs) play a crucial role in the development and recurrence of cancer. CSCs are a subpopulation within tumors capable of self-renewal and differentiation into various cell types within tumors. Furthermore, CSCs are thought to drive tumor recurrence after treatment. Even if the majority of tumor cells are eliminated by therapy, CSCs can survive and repopulate the tumor, leading to cancer relapse. However, identifying and effectively targeting CSCs remains a significant challenge. Recent studies have shown that specific antibiotics can effectively inhibit various types of CSCs prostate. (breast. ovarian. lung, pancreatic, melanoma, and glioblastoma cancers). Due to the impact of antibiotics on CSC function, targeting CSCs is a promising strategy for improving outcomes in cancer patients by preventing recurrence and enhancing treatment efficacy. Our preliminary studies have identified several extracts from bacterial antibiotic producers that can inhibit multiple CSCderived tumorsphere types (breast, lung, and prostate) in cultured human cancer cell lines. Tumorsphere formation is a widely accepted technique used to quantify CSC activity and a reliable method to screen for novel anti-CSC agents. Our objective for this Spring semester is to analyze the gene expression patterns of CSC-associated markers and their impact on tumorsphere quantity and dimensions within cultured A549 human lung cancer cells, compared to healthy lung cells. These studies will provide a baseline for assessing changes in gene expression patterns and tumorsphere morphology following treatment with bacterial extracts.

Keywords. Tumorspheres, Cancer Stem Cells, Antibiotics, Cancer Recurrence.

Acknowledgments

We would like to thank our research mentors: Anne-Lise Girard, PhD, Jill Shirokawa, PhD, and Vicky Gomez-Stallons, PhD. Additionally, we are grateful for the support provided by the UC Clermont Cronin Scholar Program.

References

- Basati G, Khaksarian M, Abbaszadeh S, Lashgarian HE, Marzban A. Cancer stem cells and nanotechnological approaches for eradication. *Stem Cell Investig.* 2019 Nov 28; 6: 38. PMCID:31853454; 10.21037/sci.2019.10.07 [doi].
- Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser
 C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by highthroughput screening. *Cell*. 2009 Aug 21; 138(4): 645-659. PMCID:19682730; 10.1016/j.cell.2009.06.034 [doi].
- Mukherjee S, Manna A, Bhattacharjee P, Mazumdar M, Saha S, Chakraborty S, Guha D, Adhikary A, Jana D, Gorain M, Mukherjee SA, Kundu GC, Sarkar DK, Das T. Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4(+) migrating cancer stem cells. *Oncogene*. 2016 Sep 15; 35(37): 4937-4948. PMCID:26923331; 10.1038/onc.2016.26 [doi].
- Nassar D, Blanpain C. Cancer stem cells: Basic concepts and therapeutic implications. *Annu Rev Pathol.* 2016 May 23; 11: 47-76.
 PMCID:27193450; 10.1146/annurev-pathol-012615-044438 [doi].
- Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells - what challenges do they pose? *Nat Rev Drug Discov*. 2014 Jul; 13(7): 497-512. PMCID:24981363; 10.1038/nrd4253 [doi].
- Tiny earth student sourcing antibiotic discovery [homepage on the Internet]. Available from: <u>https://tinyearth.wisc.edu/.</u>